Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL733703 | 0.94 | KMT2A (0.70) | KDM4EMAPTKMT2ALMNATSHR | |
| SCHEMBL4606618 | 0.92 | KDM4E (0.61) | KDM4EMAPTKMT2ALMNATSHR | |
| SCHEMBL4606621 | 0.92 | KDM4E (0.61) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL28523647 | 0.87 | KMT2A (0.76) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL626285 | 0.84 | KDM4E (0.86) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL9486225 | 0.84 | KDM4E (0.86) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL8406412 | 0.84 | KDM4E (0.86) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL27152251 | 0.84 | KDM4E (0.86) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL28650342 | 0.83 | KDM4E (0.84) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL27984227 | 0.83 | KDM4E (0.84) | KDM4EMAPTKMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001812-B2 | Trichothecene-transforming alcohol dehydrogenase, method for transforming trichothecenes and trichothecene-transforming additive | ERBER AKTIENGESELLSCHAFT (AT) | 2021-05-11 | — | — | US | claimed |
| EP-4022047-B1 | IMPROVED POLYPEPTIDES CAPABLE OF CONVERTING SUBSTRATE 3-KETO- DEOXYNIVALENOL INTO 3-EPI- DEOXYNIVALENOL | DSM Austria GmbH (AT) | 2026-04-22 | — | — | EP | disclosed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260062700-A1 | ENGINEERED RETRONS AND METHODS OF USE | RENAGADE THERAPEUTICS MAN INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250340901-A1 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | RENAGADE THERAPEUTICS MAN INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3273802-B1 | USE OF A TRICHOTHECENE-TRANSFORMING ALCOHOL DEHYDROGENASE, METHOD FOR TRANSFORMING TRICHOTHECENES AND TRICHOTHECENE-TRANSFORMING ADDITIVE | DSM Austria GmbH (AT) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025049959-A9 | GENE EDITING SYSTEMS, COMPOSITIONS, AND METHODS FOR TREATMENT OF VEXAS SYNDROME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4558624-A2 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | Renagade Therapeutics Management Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12264328-B2 | Gene editing components, systems, and methods of use | ReNAgade Therapeutics Management, Inc. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2025049959-A2 | GENE EDITING SYSTEMS, COMPOSITIONS, AND METHODS FOR TREATMENT OF VEXAS SYNDROME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230011323-A1 | REACTOR SYSTEM AND METHODS FOR USING THEREOF | PHOENIX BIOSCIENCES SA (BE) | 2023-01-12 | — | — | US | disclosed |
| WO-2023275355-A1 | REACTOR SYSTEM AND METHODS FOR USING THEREOF | QUANTOOM BIOSCIENCES S.A. (BE) | 2023-01-05 | — | — | WO | disclosed |
| US-20220372450-A1 | IMPROVED POLYPEPTIDES CAPABLE OF CONVERTING SUBSTRATE 3-KETO- DEOXYNIVALENOL INTO 3-EPI- DEOXYNIVALENOL | DSM Austria GmbH (AT) | 2022-11-24 | — | — | US | disclosed |
| EP-4022047-A1 | IMPROVED POLYPEPTIDES CAPABLE OF CONVERTING SUBSTRATE 3-KETO- DEOXYNIVALENOL INTO 3-EPI- DEOXYNIVALENOL | Erber Aktiengesellschaft (AT) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021252975-A2 | SPLIT INTEIN-BASED SELECTION FOR PEPTIDE BINDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021249980-A1 | IMPROVED POLYPEPTIDES CAPABLE OF CONVERTING SUBSTRATE 3-KETO- DEOXYNIVALENOL INTO 3-EPI-DEOXYNIVALENOL | ERBER AKTIENGESELLSCHAFT (AT) | 2021-12-16 | — | — | WO | disclosed |
| US-11001812-B2 | Trichothecene-transforming alcohol dehydrogenase, method for transforming trichothecenes and trichothecene-transforming additive | ERBER AKTIENGESELLSCHAFT (AT) | 2021-05-11 | — | — | US | disclosed |
| WO-2021038026-A1 | IMPROVED POLYPEPTIDES CAPABLE OF CONVERTING SUBSTRATE 3-KETO- DEOXYNIVALENOL INTO 3-EPI- DEOXYNIVALENOL | ERBER AKTIENGESELLSCHAFT (AT) | 2021-03-04 | — | — | WO | disclosed |
| US-20180080011-A1 | TRICHOTHECENE-TRANSFORMING ALCOHOL DEHYDROGENASE, METHOD FOR TRANSFORMING TRICHOTHECENES AND TRICHOTHECENE-TRANSFORMING ADDITIVE | ERBER AKTIENGESELLSCHAFT (AT) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062700-A1 | ENGINEERED RETRONS AND METHODS OF USE | NSUN3, RNASEH1, TRMT1L | KDM4E 3299/4885MAPT 3662/4885KMT2A 1681/4885 |
| US-20220372450-A1 | IMPROVED POLYPEPTIDES CAPABLE OF CONVERTING SUBSTRATE 3-KETO- DEOXYNIVALENOL INTO 3-EPI- DEOXYNIVALENOL | VIP, PREP, NGLY1 | KDM4E 2065/4885MAPT 4807/4885KMT2A 3042/4885 |
| US-11001812-B2 | Trichothecene-transforming alcohol dehydrogenase, method for transforming trichothecenes and trichothecene-transforming additive | ADH5, IDH3A, ADH4 | KDM4E 2762/4885MAPT 2999/4885KMT2A 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.